(NASDAQ:LFMD) LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) securities between May 7, 2025 and August 5, 2025, inclusive (the “Class Period”). LifeMD investors have until October 27, 2025 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR LIFEMD, INC
Related Questions
How will the securities fraud class action filing affect LFMD's stock price and volatility in the short term?
What is the potential financial exposure for LifeMD if the lawsuit leads to a settlement or judgment, and how might that impact the company's balance sheet and cash flow?
What precedent exists for similar class actions in the biotech/healthcare sector, and how might the outcome influence investor sentiment toward comparable companies?